Lupin launches Ganirelix Acetate Injection in US for women undergoing fertility treatment

The injection is recommended in fertility treatment to prevent luteinizing hormone (LH) surges or ovulation in women undergoing controlled ovarian hyperstimulation.

The Ganirelix Acetate Injection is a generic equivalent of Ganirelix Acetate Injection in the same dose (250 mcg/0.5 mL), the reference listed drug (RLD) of the US-based pharma company Organon USA LLC.

As per IQVIA MAT data for December 2023, the Ganirelix Acetate Injection had an estimated annual sale of $87 million in the United States.

Last week, Lupin reported a 299.6% year-on-year (YoY) growth in net profit at ₹613.1 crore for the third quarter ended December 31, 2023, compared to ₹153.4 crore in the same period last year. Its revenue from operations grew 20.2% to ₹5,197.4 crore from ₹4,322.2 crore in the corresponding quarter of the previous fiscal year.

The company’s margin rose to 20% in Q3FY24, up from 12.3% in the same period last year.

Shares of Lupin were trading 0.63% lower at ₹1,599.5 apiece in BSE at 2:06 PM.